High-grade serous ovarian cancer (HGSC) is among the most lethal gynecologic malignancies, with up to 90% of patients eventually becoming resistant to platinum-based chemotherapy. The limited availability of effective targeted therapies for platinum-resistant HGSC presents a significant clinical challenge.